Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Marczak, Joanne Williams, Michaela Loeffler (2018)
Global Deaths Attributable to High Systolic Blood Pressure, 1990-2016.JAMA, 319 21
B. Claggett, M. Packer, J. McMurray, K. Swedberg, J. Rouleau, M. Zile, P. Jhund, M. Lefkowitz, V. Shi, S. Solomon (2015)
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.The New England journal of medicine, 373 23
N. Shah, D. Lloyd‐Jones, M. O’Flaherty, S. Capewell, Kiarri Kershaw, M. Carnethon, S. Khan (2019)
Trends in Cardiometabolic Mortality in the United States, 1999-2017.JAMA, 322 8
S. Woolf, Heidi Schoomaker (2019)
Life Expectancy and Mortality Rates in the United States, 1959-2017.JAMA, 322 20
W. Haley, Olivia Gilbert, Robert Riley, J. Newman, C. Roumie, J. Whittle, I. Kronish, L. Tamariz, Alan Wiggers, D. Morisky, M. Conroy, E. Kovalik, N. Kressin, P. Muntner, D. Goff (2015)
The association between Self-Reported Medication Adherence scores and systolic blood pressure control: a SPRINT baseline data study.Journal of the American Society of Hypertension : JASH, 10 11
Joanna Paladino, J. Lakin, J. Sanders (2019)
Communication Strategies for Sharing Prognostic Information With Patients: Beyond Survival Statistics.JAMA
D. Kim, H. Uno, Lee-Jen Wei (2017)
Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results.JAMA cardiology, 2 11
A. Bress, B. Bellows, Jordan King, R. Hess, S. Beddhu, Zugui Zhang, D. Berlowitz, M. Conroy, Lawrence Fine, S. Oparil, D. Morisky, L. Kazis, N. Ruiz‐Negrón, James Powell, L. Tamariz, J. Whittle, J. Wright, M. Supiano, A. Cheung, W. Weintraub, Andrew Moran (2017)
Cost‐Effectiveness of Intensive versus Standard Blood‐Pressure ControlThe New England Journal of Medicine, 377
W. Ambrosius, K. Sink, Capri Foy, D. Berlowitz, A. Cheung, W. Cushman, Lawrence Fine, D. Goff, K. Johnson, A. Killeen, C. Lewis, S. Oparil, D. Reboussin, M. Rocco, Joni Snyder, J. Williamson, J. Wright, P. Whelton (2014)
The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT)Clinical Trials, 11
M. Muskiet, L. Tonneijck, M. Smits (2016)
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.The New England journal of medicine, 374 23
B. Claggett, J. Lachin, S. Hantel, D. Fitchett, S. Inzucchi, H. Woerle, J. George, B. Zinman (2018)
Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.Circulation, 138 15
H. Uno, B. Claggett, L. Tian, Eisuke Inoue, P. Gallo, T. Miyata, D. Schrag, M. Takeuchi, Y. Uyama, Lihui Zhao, H. Skali, S. Solomon, Susanna Jacobus, Michael Hughes, Milton Packer, Lee-Jen Wei (2014)
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 22
M. Stensrud, J. Aalen, O. Aalen, M. Valberg (2018)
Limitations of hazard ratios in clinical trials.European heart journal, 40 17
Wright (2015)
A randomized trial of intensive versus standard blood-pressure control.N Engl J Med, 373
Susan Stienen, J. Ferreira, J. Vincent, M. Busselen, Benjamin Li, J. McMurray, B. Pitt, N. Girerd, P. Rossignol, F. Zannad (2019)
Estimated Long-Term Survival With Eplerenone.Journal of the American College of Cardiology, 73 18
M. Forouzanfar, Patrick Liu, Gregory Roth, Marie Ng, S. Biryukov, L. Marczak, Lily Alexander, Kara Estep, Kalkidan Abate, T. Akinyemiju, R. Ali, N. Alvis-Guzmán, P. Azzopardi, A. Banerjee, T. Bärnighausen, Arindam Basu, T. Bekele, D. Bennett, S. Biadgilign, F. Catalá-López, V. Feigin, João Fernandes, F. Fischer, A. Gebru, P. Gona, Rajeev Gupta, G. Hankey, J. Jonas, S. Judd, Y. Khang, A. Khosravi, Y. Kim, R. Kimokoti, Y. Kokubo, D. Kolte, Alan Lopez, P. Lotufo, R. Malekzadeh, Y. Melaku, G. Mensah, A. Misganaw, A. Mokdad, Andrew Moran, Haseeb Nawaz, B. Neal, F. Ngalesoni, T. Ohkubo, F. Pourmalek, Anwar Rafay, R. Rai, D. Rojas-Rueda, Uchechukwu Sampson, I. Santos, M. Sawhney, A. Schutte, S. Sepanlou, G. Shifa, I. Shiue, B. Tedla, A. Thrift, M. Tonelli, T. Truelsen, N. Tsilimparis, K. Ukwaja, O. Uthman, T. Vasankari, N. Venketasubramanian, V. Vlassov, T. Vos, R. Westerman, Lijing Yan, Y. Yano, N. Yonemoto, M. Zaki, C. Murray (2017)
Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015JAMA, 317
Key PointsQuestionWhat are the expected associations of intensive vs standard blood pressure control with residual life span in middle-aged and older adults who are at high cardiovascular risk but without diabetes mellitus? FindingsIn this second analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) randomized clinical trial, applying age-based methods and assuming consistent treatment responses over time, it was estimated that intensive blood pressure control improves projected survival by 6 months to 3 years, depending on the age at which this treatment strategy is started. MeaningThese actuarial analyses from the SPRINT trial support the survival benefits of intensive blood pressure control, especially among middle-aged adults at risk.
JAMA Cardiology – American Medical Association
Published: May 26, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.